Kravets Iryna

Ms. Kravets Iryna


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
KIKravets Iryna
Kravets Iryna
DDDmytro V. Dudenko
Dmytro V. Dudenko
APAlexander E. Pashenko
Alexander E. Pashenko
TBTatiana A. Borisova
Tatiana A. Borisova
GTGanna M. Tolstanova
Ganna M. Tolstanova
DVDmitriy M Volochnyuk
Dmitriy M Volochnyuk
We elaborate new models for ACE and ACE2 receptors with an excellent prediction power compared to previous models. We propose promising workflows for working with huge compound collections, thereby enabling us to discover optimized protocols for virtual screening management. The efficacy of elaborated roadmaps is demonstrated through the cost-effective molecular docking of 1.4 billion compounds. Savings of up to 10-fold in CPU time are demonstrated. These developments allowed us to evaluate ACE2/ACE selectivity in silico, which is a crucial checkpoint for developing chemical probes for ACE2.

24 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ARAlexey V. Rayevsky
Alexey V. Rayevsky
APAndrii Sergiyovych Poturai
Andrii Sergiyovych Poturai
KIKravets Iryna
Kravets Iryna
APAlexander E. Pashenko
Alexander E. Pashenko
TBTatiana A. Borisova
Tatiana A. Borisova
Alexandre VarnekAlexandre Varnek
Alexandre Varnek
New models for ACE2 receptor binding, based on QSAR and docking algorithms were developed, using XRD structural data and ChEMBL 26 database hits as training sets. The selectivity of the potential ACE2-binding ligands towards Neprilysin (NEP) and ACE was evaluated. The Enamine screening collection (3.2 million compounds) was virtually screened according to the above models, in order to find possible ACE2-chemical probes, useful for the study of SARS-CoV2-induced neurological disorders. An enzymology inhibition assay for ACE2 was optimized, and the combined diversified set of predicted selective ACE2-binding molecules from QSAR modeling, docking, and ultrafast docking was screened in vitro. The in vitro hits included two novel chemotypes suitable for further optimization.